The Role of Radiation in Diffuse Large B-cell Lymphoma in Community Practice

This session provides an in-depth discussion of the role of radiation therapy in Diffuse Large B-cell Lymphoma (DLBCL). This is the most common type of lymphoma seen in a community practice, and, with recent advancements in treatment, the role of radiation therapy is evolving. Four academic radiation oncologists review the role of radiation therapy in different scenarios. The first scenario is an overview of DLBCL including the evolution of modern treatment and specific clinical and pathologic prognosticators. The second reviews the management recommendations for early-stage DLBCL and when radiation therapy is indicated. The third evaluates the role of radiation in the salvage setting for refractory or relapse. The last presentation is treatment options in the palliative setting both as a bridge to CAR-T cell therapy and non-chemotherapy patients. 

Topics:

  1. Large B-cell Lymphoma Pathology: What Rad Oncs Need to Know
    Yolanda D. Tseng, MD, MPhil
  2. Early Stage DLBCL: How to Best Harvest the Benefit of Radiation
    Bouthaina Dabaja, MD, FASTRO
  3. Incorporating Radiation Therapy in Relapsed/Refractory DLBCL 
    Christopher R. Kelsey, MD, FASTRO
  4. The Role of Radiation Therapy in Patients Undergoing CAR T-cell Therapy for Diffuse Large B-cell Lymphoma
    Timothy John Robinson, MD, PhD
  5. Q & A 

This activity is available from July 11, 2023, through 11:59 p.m. Eastern time on July 10, 2025. 

This activity was originally recorded at the 2022 ASTRO Annual Meeting Practical Radiation Oncology Program.

Target Audience

The activity is designed to meet the interests of radiation oncologists and residents. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate prognostic indicators for DLBCL.
  • Assess the role of radiation therapy in different clinical scenarios of DLBCL. 
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.
Course opens: 
07/11/2023
Course expires: 
07/10/2025
Cost:
$149.00
Rating: 
0

Arshin Sheybani, MD, is employed by the John Stoddard Cancer Center and is a shareholder with Iowa CoManagement. Dr. Sheybani holds a leadership position as a Community Oncology representative with the NCI GI Steering Committee, Anal Rectal Task Group.  

Yolanda D. Tseng, MD, MPhil, is employed by the University of Washington Medical Center and the Allen Brain Science Institute.  

Bouthaina Dabaja, MD, FASTRO, is employed by The University of Texas MD Anderson Cancer Center.  

Christopher R. Kelsey, MD, FASTRO, is employed by Duke University Medical Center and receives compensation from Johnson and Johnson and Colgate-Palmolive. 

Timothy John Robinson, MD, PhD, is employed by H. Lee Moffitt Cancer Center and Research Institute. Dr. Robinson receives research grant funding from Janssen Pharmaceuticals and is the owner/inventor of several therapeutic splicing patents.  

Christopher Hays Pope, MD, is employed by the CARTI Cancer Center and receives compensation from Radiology Associates, P.A. (RAPA).

The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.

Disclosure link: 
Committee Disclosures

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification. 

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.

Price

Cost:
$149.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

Nonmember: $149
Member: $99
Member-in-training: $49
Student/Grad Student/PGY: $49
Postdoctoral Fellow: $49
 

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.

Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.

The course and its materials will only be available on the ASTRO website until July 10, 2025, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.